| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 2.24 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
A integrase do VIH-1 é a enzima responsÔvel pela integração do ADN viral no ADN da célula hospedeira. Este processo é indispensÔvel à replicação viral, desenvolvendo-se em duas etapas independentes, o processamento 3“ e a transferência de cadeias catalisadas pela integrase. A compreensão das interacções entre a integrase e o ADN e a cinética da formação dos complexos de pré-integração evidenciaram a necessidade de descobrir inibidores das ligações do complexo integrase/ADN. Esta necessidade, permitiu desenvolver o Raltegravir e o Elvitagravir como inibidores potentes da transferência de cadeias e consequentemente da replicação viral in vivo. Estes fÔrmacos porém, não escapam aos fenómenos de resistência.
Mais de 40 substituições na integrase foram associadas ao desenvolvimento de resistência ao Raltegravir e/ou elvitagravir, in vitro. Algumas destas alterações foram também encontradas in vivo em doentes com falência terapêutica aos inibidores da integrase. Os polimorfismos do gene da integrase ocorrem de forma natural, podendo ter implicações importantes no desenvolvimento de inibidores da integrase. Foi objectivo deste estudo a determinação da prevalência de polimorfismos em doentes não tratados com inibidores da integrase e a
frequência de substituição de aminoÔcidos que ocorrem de forma natural em posições associadas a resistência. Foram indentificadas as posições polimórficas do gene pol da integrase em doentes não tratados com inibidores da integrase, confirmando-se a ausência de
mutações associadas a resistência nestes mesmos doentes. A percentagem de polimorfismos variou de acordo com a região analisada, sendo a região C-terminal a mais variÔvel. A anÔlise
mais detalhada do subtipo G contribuiu de forma significativa para caracterizar os polimorfismos existentes na população de doentes VIH-1 portuguesa. A utilização do Ćndice de Jaccard permitiu de forma inequĆvoca demonstrar a associação entre posiƧƵes polimórficas e
verificar como essas associações poderão evoluir.
The integrase catalyzes the integration of HIV-1 DNA into the host cell chromosome in a process which is essential for viral replication. Integrase performs two independent reactions, 3 Ģ-end processing and strand transfer. Deciphering the structural determinants of the interaction between integrase and its substrates as well as kinetics of this interaction shed light on the importance for pharmacological agents to target the integrase-viral DNA complex. This approach led to the development of Raltegravir and elvitagravir which turned out to be powerful inhibitors of strand transfer both in vitro and in vivo. However, like others ARVs, these compounds face resistance phenome non. Among them, about 40 substitutions in vitro have been specifically associated with the development of resistance to Raltegravir and/or Elvitagravir, some of them were also found in vivo in patients failing such integrase inhibitors. Naturally occurring integrase gene polymorphisms may have important implications for integrase inhibitors development. This study evaluated clinical HIV-1 strains from integrase inhibitors naĆÆve patients, to determine the prevalence of integrase gene polymorphisms, and the frequency of naturally occurring amino acid substitution at positions associated with integrase resistance. Polymorphic posit ions at integrase region of pol gene were identified in patients not treated with integrase inhibitors. The absence of resistance mutations to these compounds was confirmed. The percentage of polymorphisms was different within integrase regions, being the C-terminal region the one with the highest variability. Detailed analysis of G subtype contributed significantly to characterise the polymorphisms in Portuguese HIV-1 infected patients. Jacard index was used to demonstrate association between polymorphic positions and verify how those associations may evolve.
The integrase catalyzes the integration of HIV-1 DNA into the host cell chromosome in a process which is essential for viral replication. Integrase performs two independent reactions, 3 Ģ-end processing and strand transfer. Deciphering the structural determinants of the interaction between integrase and its substrates as well as kinetics of this interaction shed light on the importance for pharmacological agents to target the integrase-viral DNA complex. This approach led to the development of Raltegravir and elvitagravir which turned out to be powerful inhibitors of strand transfer both in vitro and in vivo. However, like others ARVs, these compounds face resistance phenome non. Among them, about 40 substitutions in vitro have been specifically associated with the development of resistance to Raltegravir and/or Elvitagravir, some of them were also found in vivo in patients failing such integrase inhibitors. Naturally occurring integrase gene polymorphisms may have important implications for integrase inhibitors development. This study evaluated clinical HIV-1 strains from integrase inhibitors naĆÆve patients, to determine the prevalence of integrase gene polymorphisms, and the frequency of naturally occurring amino acid substitution at positions associated with integrase resistance. Polymorphic posit ions at integrase region of pol gene were identified in patients not treated with integrase inhibitors. The absence of resistance mutations to these compounds was confirmed. The percentage of polymorphisms was different within integrase regions, being the C-terminal region the one with the highest variability. Detailed analysis of G subtype contributed significantly to characterise the polymorphisms in Portuguese HIV-1 infected patients. Jacard index was used to demonstrate association between polymorphic positions and verify how those associations may evolve.
Descrição
Palavras-chave
Ciências biomédicas Doenças infecciosas HIV Gene pol Enzimas Polimorfismo
Contexto Educativo
Citação
Editora
Instituto de Higiene e Medicina Tropical
